BindingDB

The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.

BindingDB contains 3.2M data for 1.4M Compounds and 11.4K Targets. Of those, 1.6M data for 748K Compounds and 4.8K Targets were curated by BindingDB curators. BindingDB is a FAIRsharing resource.

If BindingDB was of value to your research, please take a moment to donate to this nonprofit project. Your donation will let us provide you with more data and improved service.

Donate Now

To help with training and testing AI and other models, BindingDB downloads and search results now provide the publication date and BindingDB curation date of each measurement.

Advanced Search

19 articles for thisTarget

The following articles (labelled with PubMed ID or TBD) are for your review

PMID
Data
Article Title
Organization
Fragment and Structure-Based Drug Discovery for a Class C GPCR: Discovery of the mGlu5 Negative Allosteric Modulator HTL14242 (3-Chloro-5-[6-(5-fluoropyridin-2-yl)pyrimidin-4-yl]benzonitrile).EBI
Heptares Therapeutics
Biophysical fragment screening of theß1-adrenergic receptor: identification of high affinity arylpiperazine leads using structure-based drug design.EBI
Heptares Therapeutics
Biophysical mapping of the adenosine A2A receptor.EBI
Heptares Therapeutics
Identification of novel adenosine A(2A) receptor antagonists by virtual screening.EBI
Heptares Therapeutics
Discovery of 1,2,4-triazine derivatives as adenosine A(2A) antagonists using structure based drug design.EBI
Heptares Therapeutics
Progress in structure based drug design for G protein-coupled receptors.EBI
Heptares Therapeutics
Small Molecule CXCR3 Antagonists.EBI
Heptares Therapeutics
Controlling the Dissociation of Ligands from the Adenosine A2A Receptor through Modulation of Salt Bridge Strength.EBI
Heptares Therapeutics
Inhibitors of histone deacetylaseBDB
The General Hospital
FGFR inhibitor and application thereofBDB
Betta Pharmaceuticals
Heterocyclic compound, its preparation method, and pharmaceutical composition comprising the sameBDB
Daewoong Pharmaceutical
FXR (NR1H4) modulating compoundsBDB
Gilead Sciences
Inhibitors of cyclin-dependent kinase 7 (CDK7)BDB
Dana-Farber Cancer Institute
Piperidine derivatives for use in the treatment or prevention of psychiatric and neurological conditionsBDB
Takeda Pharmaceutical
Isoindolinone inhibitors of the MDM2-p53 interaction having anticancer activityBDB
Astex Therapeutics
Secondary alcohol substituted triazoles as PDE10 inhibitorsBDB
Merck Sharp & Dohme
Substituted aminoquinazolines useful as kinases inhibitorsBDB
TBA
Azaindole derivatives as tyrosine kinase inhibitorsBDB
Principia Biopharma
Anti-cancer compound and pharmaceutical composition containing the sameBDB
Sanofi